Callan Family Office LLC Acquires New Position in Illumina, Inc. $ILMN

Callan Family Office LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, HoldingsChannel reports. The fund acquired 10,254 shares of the life sciences company’s stock, valued at approximately $1,803,000.

A number of other institutional investors have also recently bought and sold shares of ILMN. HighPoint Advisor Group LLC raised its position in shares of Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares during the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the period. Finally, Panagora Asset Management Inc. grew its stake in shares of Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of several analyst reports. Royal Bank Of Canada increased their target price on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. TD Cowen boosted their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Stifel Nicolaus upped their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Leerink Partners increased their price target on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Finally, Barclays lifted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $188.40.

Insiders Place Their Bets

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is owned by company insiders.

Illumina Price Performance

ILMN opened at $219.40 on Monday. The stock has a market cap of $33.13 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.09 and a beta of 1.45. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $220.43. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a fifty day simple moving average of $188.01 and a 200 day simple moving average of $152.52.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.